Could a simpler HIV pill protect moms and babies?

NCT ID NCT07616739

Not yet recruiting Disease control Sponsor: Fundación Huésped Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test a two-drug HIV pill (Dolutegravir/Lamivudine) in 210 pregnant women who have never taken HIV medication. The goal is to see if it controls the virus and prevents passing HIV to their babies. Participants will be compared to those on standard three-drug therapy. The study will also monitor side effects and birth outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dolutegravir/Lamivudine (a two-drug HIV pill)
What this could lead to: If successful, this could show that a simpler two-drug regimen is safe and effective for pregnant women with HIV, reducing the risk of passing the virus to their babies.
What could go wrong: This is a Phase 4 study, so the drugs are already approved, but results may not apply to all populations. There is a risk of side effects or the two-drug combo being less effective than standard three-drug therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Complexo do Hospital de Clínicas da UFPR/Ebserh

Curitiba, Pernambuco, 80430-000, Brazil
Fundação Bahiana de Infectologia

Salvador, Estado de Bahia, 40110-160, Brazil
Hospital General de Agudos Dr. Cosme Argerich

Ciudad Autónoma de Buenos Aires, Buenos Aires, C1155AHD, Argentina
Hospital Geral de Nova Iguaçu

Nova Iguaçu, Rio de Janeiro, 26030-380, Brazil
Hospital Nacional Profesor Alejandro Posadas

El Palomar, Buenos Aires, B1684, Argentina
Hospital de Agudos J.A. Fernandez

Ciudad Autónoma de Buenos Aires, Buenos Aires, C1425AGP, Argentina
Hospital de Agudos Paroissien

Isidro Casanova, Buenos Aires, B1765, Argentina
RDSS - Ricardo Sobhie Diaz & Cia Solucoes Cientificas Ltda - Ricardo Diaz Scientific Solution

São Paulo, São Paulo, 04037-030, Brazil
Sanatorio Güemes

Ciudad Autónoma de Buenos Aires, Buenos Aires, C1188AAF, Argentina
Universidade Federal do Rio Grande do Norte

Natal, Rio Grande do Norte, 59075-070, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.